Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., filed a Form 4 on November 20, 2026, disclosing the sale of 32,717 shares of common stock on November 18, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Shares Sold: Thomas Catinazzo disposed of 32,717 shares of Relay Therapeutics common stock on November 18, 2026.
  • Weighted Average Price: The reported weighted average sale price was $16.51 per share, with individual trades executed in a range from $16.30 to $17.12.
  • 10b5-1 Plan: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Catinazzo on October 30, 2025.
  • Remaining Ownership: Following the transaction, Catinazzo beneficially owned 70,948 shares directly, including 3,269 shares underlying restricted stock units.
  • Transaction Code: The sale was recorded under transaction code S (open-market sale).

Thomas Catinazzo's November 2026 Common Stock Sale at Relay Therapeutics

According to the Form 4 filed with the SEC on November 20, 2026, Thomas Catinazzo, serving as Chief Financial Officer of Relay Therapeutics, Inc. (NASDAQ:RLAY), sold 32,717 shares of the company's common stock on November 18, 2026. The filing indicates the transaction was a disposition (code S), carried out directly by the reporting person.

The filing discloses that the sale was executed in multiple trades at prices ranging from $16.30 to $17.12 per share, with a weighted average sale price of $16.51. The filing notes that Catinazzo "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."

The transaction was carried out under a Rule 10b5-1 trading plan that Catinazzo adopted on October 30, 2025, as stated in the filing's explanation of responses. Following the reported sale, Catinazzo's direct beneficial ownership stood at 70,948 shares, a figure the filing states includes 3,269 shares underlying restricted stock units. The Form 4 was signed by Soo-Yeun Lim as Attorney-in-Fact on November 20, 2026.

What Was Disclosed

The filing reported the open-market sale of 32,717 shares of Relay Therapeutics common stock by CFO Thomas Catinazzo on November 18, 2026, at a weighted average price of $16.51, under a pre-established Rule 10b5-1 plan, leaving him with 70,948 shares beneficially owned.